BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience

Thermo Fisher Introduces Hypulse™ System to Transform XPS Depth-Profiling

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Hypulse™ Surface Analysis System. This inn...

September 23, 2025 | News

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

September 22, 2025 | News

Lenovo Launches GOAST v4.0 Slashing Genome Analysis to 24 Minutes with 3x Higher Throughput

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries Lenovo shared updates ...

September 22, 2025 | News

EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications

EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...

September 18, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

September 15, 2025 | News

YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies

YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...

September 12, 2025 | News

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Cytiva and WhiteLab Genomics Partner to Accelerate AAV Genomic Medicine Development

Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timelin...

September 11, 2025 | News

Innorna completes Phase II enrollment for IN006, the first bivalent RSV mRNA vaccine

Innorna announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory...

September 11, 2025 | News

AGC Biologics Seattle Site Achieves New Heights in Manufacturing Excellence

Manufacturing excellence positions Seattle site as premier destination for mammalian and microbial biologic production in thriving Pacific Northwest life...

September 11, 2025 | News

Stay Connected